Adverse events: all ‐ central nervous system events (e.g. headache, seizures) (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: all ‐ central nervous system events (e.g. headache,… compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Adverse events: all ‐ other events ‐ not listed above (e.g. dysuria, neck pain, eye discomfort) (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: all ‐ other events ‐ not listed above (e.g.… compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Treatment‐related adverse effects · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Degree of penile curvature · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
1 finding from 1 review
Treatment discontinuation · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
It is very uncertain whether injectional interferon alpha‐2B changes discontinuation from treatment compared with saline (very low certainty).
1 finding from 1 review
Outcomes ( · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported ability to have intercourse · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Smoking cessation · people who smoke
Combination leads to higher smoking cessation compared with single‐form nicotine replacement therapy (high certainty).
1 finding from 1 review
Overall serious adverse events · people who smoke
Combination showed no clear difference in overall serious adverse events compared with single‐form nicotine replacement therapy (low certainty).
1 finding from 1 review
Treatment withdrawal · people who smoke
It is very uncertain whether combination changes treatment withdrawals compared with single‐form nicotine replacement therapy (very low certainty).
1 finding from 1 review
Frequency of transfusion (transfused volume/year) · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Haemoglobin (g/dL) · people with non‐transfusion‐dependent β‐thalassaemia
1 finding from 1 review
Measures of HbF · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with non‐transfusion‐dependent β‐thalassaemia
1 finding from 1 review
Intervention not reported
High‐dose atropine (≥ 0.5%) · children with progressive myopia (38 studies, 6525 participants in analyses) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
High‐dose atropine (≥ 0.5%) · children with progressive myopia (26 studies, 4949 participants in the analysis) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (26 studies, 4949 participants in the analysis) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review